Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Key points are not available for this paper at this time.

Pivot et al. (2018) studied this question.

View Full Paper

Ask AI

Bookmark